<DOC>
	<DOCNO>NCT00287469</DOCNO>
	<brief_summary>The purpose study determine hepatitis E vaccine safe able prevent symptomatic liver disease due hepatitis E virus .</brief_summary>
	<brief_title>A Safety Efficacy Study Hepatitis E Vaccine Nepal .</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled 2 study group ( vaccine placebo ) . Three dos study vaccine give accord 0 , 1 , 6 month schedule . Vaccine efficacy assess maintain active surveillance clinical hepatitis every 2 week hospital base surveillance full duration trial . Total plan study population 2000 eligible subject ( 1000 vaccine group 1000 placebo group ) . Total vaccinated cohort analysis reactogenicity 200 ( 100 vaccine group 100 placebo group ) . Volunteers enroll follow evidence symptomatic liver disease approximately 2 year , become ill admitted hospital care . To evaluate safety , randomly designate subset monitor 7 day vaccination solicit specific symptom injection site generally . Additionally , adverse event collect 30 day vaccine dose serious adverse event collect throughout trial .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 18 year age old time first vaccination . Written oral witness ( subject illiterate ) inform consent obtain subject Free obvious health problem establish medical history enter study If subject female , must negative serum pregnancy test within 48 hour prior vaccination must agree avoid become pregnant course vaccination 30 day last dose vaccine . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration chronic ( defined 14 day ) immunosuppressant immune modify drug within six month vaccination . For corticosteroid , mean prednisone , equivalent , * 0.5 mg/kg/day . Inhaled topical steroid allow . Any chronic drug therapy continue study period exception contraceptive agent , homeopathic remedy , vitamin , mineral dietary supplement drug therapy discretion investigator . Planned administration/administration vaccine foreseen study protocol within 30 day first dose study vaccine , exclude tetanus toxoid rabies vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , report volunteer ( test HIV perform ) . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Acute disease define presence moderate severe illness without fever . All vaccine could administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e. , oral temperature &lt; 38.0°C ( 100.4°F ) . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine history . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant female . History chronic alcohol consumption ( define consumption equivalent 4 12 ounce beer 4 time week ) and/or intravenous drug abuse . Antibodies rHEV ( * 20 WR U/mL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis E</keyword>
	<keyword>clinical hepatitis</keyword>
	<keyword>vaccine</keyword>
	<keyword>efficacy</keyword>
	<keyword>Nepal</keyword>
</DOC>